Skip to main content

HBM Healthcare Investments nominates Dr Elaine Jones for the election to the Board of Directors


The Board of Directors of HBM Healthcare Investments AG is nominating Dr Elaine Jones for the election to the Board of Directors at the Annual General Meeting on 18 June 2021. Dr Jones is an experienced biopharmaceutical executive with more than 20 years of investment experience as a life science-focused venture capitalist.

Dr Jones was Vice President at Pfizer Ventures, the corporate venture capital arm of Pfizer from 2008 to 2019, where she was responsible for managing biotechnology and healthcare investments. Prior to Pfizer, Dr Jones was a General Partner with EuclidSR Partners, a venture fund focused on the life sciences and technology sectors, as well as in areas where those industries converge to enhance drug discovery and development. She began her investing career in 1999 at S.R. One, the corporate investment fund of GlaxoSmithKline. During her career, she served on the boards of more than 20 early to mid-stage biotechnology, therapeutic and pharmaceutical companies. Previously, she was the Director of Scientific Licensing at SmithKline Beecham and a research scientist in the research and development division of SmithKline Beecham Pharmaceuticals.

Dr Jones received a B.S. in Biology from Juniata College and a Ph.D. in Microbiology from the University of Pittsburgh and conducted post-doctoral research at the National Institutes of Health in the National Institute of Allergy and Infectious Disease. She currently serves on the boards of the three public companies Gritstone (as Chair) CytomX and NextCure, is the Chair of Mironid (UK) and a member of the Advisory Board of Novartis Venture Fund.


For further information, please contact Dr Andreas Wicki on +41 41 710 75 77, or at